The US government owns the original patent on Cannabinoids (Cannabis extracts) and lists them as “Neural Protectants”
Few people know that the US
government owns the original patent on Cannabinoids (Cannabis extracts)
and lists them as “Neural Protectants” meaning they protect and repair
nerves in the brain and body.
A psychology professor at Bonn University in Germany Andreas Zimmer, lead a study using cannabis extracts and their effects on memory and cognition in senior mice. He found that using THC (Marijuana) for 28 days, improved memory and learning abilities in older mice as compared to younger mice in both a water maze, and with object recognition tests.
The DEA classifies Marijuana as a schedule 1 drug and as such is closely regulated and controlled, requiring a prescription from a registered doctor and purchase (in states where it’s legal) from licensed dispensaries.
The German scientists discovered that nerve synapses within the hippocampus (responsible for emotions and memory) in the brain of the older animals were firing as actively as the younger ones when the THC was used. If the same holds true on humans, there may be some real applications for patients with Alzheimer’s and dementia. Zimmer believes that these findings help to better understand use of MMJ (medical marijuana) as a bonefide medical treatment.
Zimmer and colleagues tried three directions for their research. First low doses of THC were given to mice, at 2, 12. and 18 months respectively; this equates to 20, 58 and 64 years old in human years.
Involving both older and younger mice, the researchers applied three tests within the first 28 days: a water maze, location of an object, and recognition of a partner. Initially the older mice performed poorly in comparison to the younger mice as would be expected. However, once the older mice were given low dose THC, their scores improved dramatically in all three areas. Using this protocol, Zimmer notes they exercised caution not to render abnormal side-effects or harm to the animals. His hope for the future is to apply this research to elderly humans.
Oxford University associate professor in clinical neurosciences Zameel Cader, commented that this THC study showed promise for humans with dementia and Alzheimer’s and cannabinoids in general.
He cautions not to jump the gun just yet as these tests were on animals not humans. He further wonders when it would be most appropriate to administer this as a medication, over what length of time, and how long it would take to see results.
There is concern among some people regarding the alleged “addiction” with THC and its’ long term effects. Despite some nay-sayers, the use of Marijuana is rising among seniors and adults.
The National Survey of Drug Use and Health (NSDUH) reported that cannabis use tripled from 2002 thru 2014; use in adults 50-64 years old went from 2.9% to 9%
Many researchers, scientists and healthcare professionals from all around the globe are discovering that a Hemp plant derivative called Cannabidiol or CBD is likewise extremely effective in treating nearly all neurological conditions including Alzheimer’s, ALS, Parkinson’s, and mental disorders, without the unwanted side-effects of THC.
A psychology professor at Bonn University in Germany Andreas Zimmer, lead a study using cannabis extracts and their effects on memory and cognition in senior mice. He found that using THC (Marijuana) for 28 days, improved memory and learning abilities in older mice as compared to younger mice in both a water maze, and with object recognition tests.
The DEA classifies Marijuana as a schedule 1 drug and as such is closely regulated and controlled, requiring a prescription from a registered doctor and purchase (in states where it’s legal) from licensed dispensaries.
The German scientists discovered that nerve synapses within the hippocampus (responsible for emotions and memory) in the brain of the older animals were firing as actively as the younger ones when the THC was used. If the same holds true on humans, there may be some real applications for patients with Alzheimer’s and dementia. Zimmer believes that these findings help to better understand use of MMJ (medical marijuana) as a bonefide medical treatment.
Zimmer and colleagues tried three directions for their research. First low doses of THC were given to mice, at 2, 12. and 18 months respectively; this equates to 20, 58 and 64 years old in human years.
Involving both older and younger mice, the researchers applied three tests within the first 28 days: a water maze, location of an object, and recognition of a partner. Initially the older mice performed poorly in comparison to the younger mice as would be expected. However, once the older mice were given low dose THC, their scores improved dramatically in all three areas. Using this protocol, Zimmer notes they exercised caution not to render abnormal side-effects or harm to the animals. His hope for the future is to apply this research to elderly humans.
Oxford University associate professor in clinical neurosciences Zameel Cader, commented that this THC study showed promise for humans with dementia and Alzheimer’s and cannabinoids in general.
He cautions not to jump the gun just yet as these tests were on animals not humans. He further wonders when it would be most appropriate to administer this as a medication, over what length of time, and how long it would take to see results.
There is concern among some people regarding the alleged “addiction” with THC and its’ long term effects. Despite some nay-sayers, the use of Marijuana is rising among seniors and adults.
The National Survey of Drug Use and Health (NSDUH) reported that cannabis use tripled from 2002 thru 2014; use in adults 50-64 years old went from 2.9% to 9%
Many researchers, scientists and healthcare professionals from all around the globe are discovering that a Hemp plant derivative called Cannabidiol or CBD is likewise extremely effective in treating nearly all neurological conditions including Alzheimer’s, ALS, Parkinson’s, and mental disorders, without the unwanted side-effects of THC.
No comments:
Post a Comment